How can you develop a model for determing cost of goods for m-lovenox without 100% participation from Novartis and basically "trusting" them to segregate their costs for this particular generic?
That’s what audits are for.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”